Corbus Pharmaceuticals stock costs EUR 3.86 with volume 36.43 percent above average

Published on 10/15/2026 at 22:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cash and investments totaled USD 118.0 million on June 30, 2026. Corbus Pharmaceuticals stock costs EUR 3.86 on October 15, 2026 at 10:26 p.m. CEST.

Volume and valuation

Trading volume reached 1,089,233 shares on October 15, 2026.
Cash and investments totaled USD 118.0 million on June 30, 2026.
Corbus Pharmaceuticals stock costs EUR 3.86 at Lang & Schwarz on October 15, 2026 at 10:26 p.m. CEST.
Estimated earnings are scheduled for November 16, 2026.

CRBP, US21833P3010, Illustration mit AI erstellt.

Trading volume for Corbus Pharmaceuticals reached 1,089,233 shares on October 15, 2026, 36.43 percent above its average of 798,373 shares. The stock was trading at EUR 3.86 at Lang & Schwarz on October 15, 2026 at 10:26 p.m. CEST.

Volume exceeds average

The activity came as Corbus Pharmaceuticals continued to develop treatments in oncology and obesity. The company describes its pipeline as including CRB-701, CRB-601 and CRB-913, with CRB-701 targeting Nectin-4 in cancer cells, according to Corbus Pharmaceuticals.

Cash and investments stood at USD 118.0 million on June 30, 2026, while the standardized second-quarter figures show a net loss of USD 35.0 million and operating cash flow of minus USD 29.6 million. Those figures frame the stock as a development-stage biotechnology company whose valuation depends heavily on clinical progress, according to TipRanks.

Yearly range stays wide

The USD 4.33 last price on Nasdaq at 4:00 p.m. ET on October 15, 2026 was above the USD 4.23 yearly low and far below the USD 20.56 yearly high. The latest market profile places Corbus Pharmaceuticals at a USD 83.7 million market capitalization and gives it a negative P/E ratio of minus 0.67.

MarketWatch identifies Nasdaq as the primary listing and reports a year-to-date decline of 41.28 percent as of October 14, 2026. The same profile lists 19.34 million shares outstanding and an average volume of 775,390 shares, while the current activity is higher, according to MarketWatch.

Valuation and earnings date

Yahoo Finance lists November 16, 2026 as the estimated earnings date for Corbus Pharmaceuticals. That date gives investors the next scheduled point for a fresh review of cash use, clinical progress and the company outlook, according to Yahoo Finance.

Comparison with peers

CRBP (Nasdaq, USD): , P/E minus 0.67, market capitalization USD 83.7 million
Immunocore Holdings (Nasdaq, USD): plus 4.02 percent, P/E minus 154.91, market capitalization USD 1.5 billion
Alkermes (Nasdaq, USD): plus 2.61 percent, P/E 104.70, market capitalization USD 6.7 billion

Price after the US close

Corbus Pharmaceuticals stock was trading at EUR 3.86 at Lang & Schwarz on October 15, 2026 at 10:26 p.m. CEST. The Nasdaq last price was USD 4.33 on October 15, 2026 at 4:00 p.m. ET.

The further course of trading is shown by the continuously updated real-time quote of Corbus Pharmaceuticals stock.